These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 11052337)
21. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Jorga KM Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520 [TBL] [Abstract][Full Text] [Related]
22. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Rajput AH; Martin W; Saint-Hilaire MH; Dorflinger E; Pedder S Neurology; 1998 May; 50(5 Suppl 5):S54-9. PubMed ID: 9591523 [TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of COMT inhibitors. Brooks DJ Neurology; 2004 Jan; 62(1 Suppl 1):S39-46. PubMed ID: 14718679 [TBL] [Abstract][Full Text] [Related]
25. Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Martignoni E; Cosentino M; Ferrari M; Porta G; Mattarucchi E; Marino F; Lecchini S; Nappi G Neurology; 2005 Dec; 65(11):1820-2. PubMed ID: 16344532 [TBL] [Abstract][Full Text] [Related]
26. Tolcapone: COMT inhibition for the treatment of Parkinson's disease. Fahn S Neurology; 1998 May; 50(5 Suppl 5):S1-2. PubMed ID: 9591515 [No Abstract] [Full Text] [Related]
32. First COMT inhibitor approved for Parkinson's disease. Am J Health Syst Pharm; 1998 Mar; 55(6):524, 526. PubMed ID: 9544322 [No Abstract] [Full Text] [Related]
33. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis. Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736 [TBL] [Abstract][Full Text] [Related]
34. [Comparison of the safety of the medicinal product in the European Union and the United States, tolcapone (Tasmar) -- COMT inhibitor as the analyzed example]. Konopka M; Członkowski A Neurol Neurochir Pol; 2005; 39(6):490-6. PubMed ID: 16355307 [TBL] [Abstract][Full Text] [Related]
35. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Smith KS; Smith PL; Heady TN; Trugman JM; Harman WD; Macdonald TL Chem Res Toxicol; 2003 Feb; 16(2):123-8. PubMed ID: 12588182 [TBL] [Abstract][Full Text] [Related]
36. Tolcapone: a novel approach to Parkinson's disease. Micek ST; Ernst ME Am J Health Syst Pharm; 1999 Nov; 56(21):2195-205. PubMed ID: 10565698 [TBL] [Abstract][Full Text] [Related]
37. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116 [TBL] [Abstract][Full Text] [Related]
38. A preclinical re-evaluation of the safety profile of tolcapone. Borroni E; Cesura AM; Gatti S; Gasser R Funct Neurol; 2001; 16(4 Suppl):125-34. PubMed ID: 11996507 [No Abstract] [Full Text] [Related]
39. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084 [TBL] [Abstract][Full Text] [Related]
40. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA. Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]